a, Schematic of Camui CaMKII sensor (numbers are amino acid sequence numbers; Assn is the association domain of CaMKII). b, Direct (Ca 21 /CaM) or autonomous (1EGTA) activation of Camui measured in lysates after HEK-cell exposure to indicated glucose concentration. F CFP /F YFP , ratio of fluorescence of cyan fluorescent protein (CFP) to fluorescence of yellow fluorescent protein (YFP). WT, wild type. c, S279 mutation does not affect Ca 21 /CaM, phosphorylation, or oxidation-dependent activity. d, Glucose-dependent Camui activation is ablated by KN-93 or Ca 21 chelation (1EGTA). e, Increased glucose concentration enhances pacing-or Iso-induced CaMKII activity. f, Glucose-dependent CaMKII activity measured by 32 P incorporation. g, Glucose-dependent Camui activation is enhanced by Thm-G and ablated by O-GlcNAc inhibition (1DON) (n 5 3 for all data points). Data show mean 6 standard error of the mean (s.e.m.); experiments are with three preparations done in triplicate, unless indicated. *P , 0.05 versus control.
Post-translational modification by O-GlcNAc ('O-GlcNAcylation') can alter protein function 10 , and such regulation is seen in heart 11, 12 and brain proteins [13] [14] [15] . O-GlcNAcylation is enhanced by elevated glucose concentration, which raises levels of the direct substrate (uridine diphosphate (UDP)-N-acetylglucosamine) of the enzyme O-GlcNAc transferase (OGT). O-GlcNAc groups are removed by the enzyme O-GlcNAcase. We tested whether direct O-GlcNAcylation might mediate glucoseinduced autonomous CaMKII activation, analogous to autophosphorylation in the conserved CaMKII regulatory domain (Extended Data Fig. 1e ). Two consensus O-GlcNAcylation sites are T286 and S279. T286A-mutant Camui only slightly limited glucose-induced autonomous activation (Extended Data Fig. 1b ), but that could be indirect, through synergy between O-GlcNAcylation at another site enhancing T286 autophosphorylation.
Remarkably, S279A-mutant Camui abolished glucose-induced autonomous CaMKII activation ( Fig. 1b , black bars). Importantly, S279A had no effect on either direct CaMKII activation or on autonomous activity induced by autophosphorylation or oxidation ( Fig. 1c ). Thus, S279 may be a specific target for O-GlcNAc-mediated CaMKII activity during hyperglycaemia.
High glucose did not alter the CaMKII activation state in cells kept in Ca 21 -free, EGTA-containing conditions ( Fig. 1d ). When cells were exposed to elevated glucose (and normal Ca 21 ), the subsequently measured maximal Ca 21 /CaM-dependent activity was enhanced ( Fig. 1d , middle bars). Pre-treatment with the CaMKII inhibitor KN-93 (which locks CaMKII in the closed high-FRET state) prevented autonomous activation by high glucose, even in the presence of Ca 21 /CaM. Rat cardiomyocytes expressing Camui and exposed to high glucose (without stimulation) for 24 h showed no significant change in baseline CaMKII activation versus low-glucose myocytes (Fig. 1e ). However, increasing intracellular [Ca 21 ], either by pacing (0.5 Hz for 30 s) or isoprenaline (Iso; 100 nM for 20 min) yielded significantly greater CaMKII activation at higher glucose concentrations. These observations suggest that O-GlcNAcylation of CaMKII is analogous to autophosphorylation and oxidation, requiring initial opening via Ca 21 /CaM.
To confirm our Camui observations, we cultured rat myocytes for 24 h in varying glucose concentrations and measured autonomous CaMKII activity (6 Iso) using a standard assay ( 32 P incorporation into a CaMKII substrate; Fig. 1f ). CaMKII activity was increased by glucose .200 mg dl 21 , and by combined Iso and high glucose. O-GlcNAcylation is dynamic in cells and limited by glucose availability 10 and the enzymatic functions of OGT 16 and O-GlcNAcase 17 . Specific inhibition of glutamine-fructose amidotransferase by 50 mM diazo-5oxonorleucine (DON) to prevent production of the OGT substrate (Fig. 4g) , and hence O-GlcNAcylation, abolished glucose-induced autonomous CaMKII activation ( Fig. 1g ). Conversely, inhibition of O-GlcNAcase with 100 nM thiamet-G (Thm-G) promotes O-GlcNAc modification and enhanced myocyte CaMKII activity in conditions of elevated glucose concentration. Mutant-S279A Camui was not appreciably activated by high glucose in intact cells (Extended Data Fig. 1d ). Thus, glucose-induced CaMKII activity involves S279 and an O-GlcNAcdependent pathway.
To determine the extent of CaMKII O-GlcNAcylation in heart and brain, we used a custom-designed antibody that specifically recognizes this modification 15 . The fraction of CaMKII that was O-GlcNAc-modified and autophosphorylated was increased in rat myocytes cultured in high relative to normal glucose (350 versus 150 mg dl 21 , Fig. 2a ), confirming that high glucose induces O-GlcNAc modification and increased activation of CaMKII. O-GlcNAc modification of CaMKII was blocked by KN-93 and in the S279A mutant ( Fig. 2a ), whereas it was enhanced by treating myocytes with 100 nM Iso 20 min before lysis (Extended Data Fig. 2a ). We verified that the antibody reacted specifically to O-GlcNAc by immunoblots before and after b-elimination reactions that specifically cleaved O-linked glycans without degrading proteins (Extended Data Fig. 2b ). The O-GlcNAc antibody no longer recognized high-glucose-treated CaMKII after b-elimination, but CaMKII levels were unaltered. O-GlcNAc modification of CaMKII was also disrupted by 50 mM DON and enhanced by 100 nM Thm-G (Extended Data Fig. 2c ). We subjected peptides encoding the regulatory domain of CaMKII to in vitro labelling with O-GlcNAc transferase and confirmed with O-GlcNAc-specific and CaMKII-phospho-T286-specific (P-T286) antibodies show that high glucose concentration (350 mg dl 21 ) increases O-GlcNAcylation and activation of CaMKII, but not in S279A-mutant CaMKII or after KN-93 treatment (n 5 3 myocyte preparations). IP, immunoprecipitate. b, The ratio of O-GlcNAc-modified to total CaMKII is increased in heart (n 5 6 hearts per group) and brain (n 5 3 brains per group) from diabetic versus control non-diabetic human patients. Ctrl, control. HF, heart failure. c, O-GlcNAc modification of CaMKII is also increased in heart and brain from diabetic rats compared with wild-type controls (number of rats indicated). Data are shown as mean 6 s.e.m. *P , 0.05, **P , 0.01 versus control.
LETTER RESEARCH the S279 site as a target for O-GlcNAc modification using electrontransfer-dissociation mass spectrometry (ETD-MS; Extended Data Fig. 3 ). CaMKII expression is increased in patients with heart failure 18 , and elevated CaMKII expression and activity have been implicated in the transition to heart failure 19, 20 . Using the O-GlcNAc-specific antibody, we probed cardiac samples (holding total CaMKII constant) from patients with heart failure and diabetes (blood glucose .400 mg dl 21 ), alongside failing and non-failing non-diabetic hearts (blood glucose ,200 mg dl 21 ). The fraction of CaMKII that was O-GlcNAc modified was doubled in heart failure patients and nearly tripled in heart failure patients with diabetes versus those with non-failing, non-diabetic hearts (Fig. 2b) . Similarly, brain samples from people with diabetes had significantly increased O-GlcNAc-modified CaMKII relative to those from nondiabetic people. In a diabetic rat model with reduced insulin secretion and blood glucose .600 mg dl 21 (ref. 21) , CaMKII O-GlcNAcylation was greatly elevated in heart and brain samples versus in control rats ( Fig. 2c ). Interestingly, CaMKII autophosphorylation was also enhanced in cardiac tissue from diabetic rats (Extended Data Fig. 2d ), consistent with synergistic CaMKII activation through these mechanisms. Taken together, our data demonstrate that CaMKII O-GlcNAcylation and activation occur in the heart and brain of diabetic subjects.
Ryanodine receptor (RyR) phosphorylation by CaMKII enhances cardiac sarcoplasmic reticulum Ca 21 release events (Ca 21 sparks and waves) [22] [23] [24] . In intact isolated myocytes, GlcNAcase inhibition with Thm-G or elevated glucose concentration alone increased Ca 21 spark and wave frequency ( Fig. 3a-c) . The Thm-G-induced Ca 21 spark increase occurred without altered sarcoplasmic reticulum Ca 21 content (Extended Data Fig. 4a ) and was prevented by the CaMKII inhibitor KN-93, but not its inactive analogue KN-92. Combining Thm-G treatment with increased glucose concentration (350 mg dl 21 ) markedly increased Ca 21 sparks and waves, consequently depleting sarcoplasmic reticulum Ca 21 (Extended Data Fig. 5 ). Thus, hyperglycaemia and reduced GlcNAcase activity synergize in activating sarcoplasmic reticulum Ca 21 release. Acute blockade of either CaMKII (1KN-93) or O-GlcNAcylation (1DON) prevented glucose-dependent Ca 21 sparks (Fig. 3c ), but did not alter sarcoplasmic reticulum Ca 21 load (Extended Data Fig. 4b ). Ca 21 spark frequency versus control was neither altered by DON ( Fig. 3c ) nor the non-metabolizable sugar mannitol (Extended Data Fig. 4c ). Thus, glucoseinduced arrhythmogenic Ca 21 waves occur through a CaMKII-and O-GlcNAc-dependent mechanism.
To test whether CaMKIId (the dominant cardiac isoform) is required for O-GlcNAc-dependent effects on sarcoplasmic reticulum Ca 21 release, we used myocytes from CaMKIId-knockout mice. Neither Ca 21 transient amplitude nor sarcoplasmic reticulum Ca 21 load (Extended Data Fig. 4d , e) were altered by acute Thm-G exposure in wild-type or CaMKIIdknockout mouse cells. Ca 21 spark frequency was significantly enhanced by Thm-G in wild-type but not in CaMKIId-knockout myocytes (Fig. 3d ).
Using optical mapping in Langendorff-perfused rat hearts exposed to 400 mg dl 21 glucose, we observed a significant increase in premature ventricular complexes (PVCs) compared with baseline ( Fig. 4a ), Glc-6-P GlcN-6-P UDP-GlcNAc n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Glc DADs Thm-G n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n nn 
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consistent with observations of enhanced PVCs in human diabetic patients 25 . This effect was attenuated by inhibiting either CaMKII (using KN-93) or O-GlcNAc (using DON) ( Fig. 4b ). We also mapped intracellular [Ca 21 ] ([Ca 21 ] i ) and voltage simultaneously. Epicardial activation during PVCs was typified by markedly slowed conduction and activation times compared with normal activation (Fig. 4c ). Additionally, spontaneous diastolic [Ca 21 ] i elevation preceded the action potential upstroke in high glucose conditions (Fig. 4d) , an effect prevented by blocking OGT using DON pre-treatment (Extended Data Fig. 6a, b ). We also found higher in vivo arrhythmia susceptibility in normal and diabetic rats during challenge with caffeine and dobutamine (Fig. 4e, f) . DON pre-treatment ablated arrhythmias induced by caffeine and dobutamine in diabetics, but had no effect on baseline or caffeine/ dobutamine-induced arrhythmia in non-diabetic rats. We also confirmed that CaMKII activity is elevated in diabetic rat hearts, and that this effect is blunted by pre-treatment of rats with DON (Extended Data Fig. 6c ), consistent with O-GlcNAc-and CaMKII-dependent hyperglycaemiainduced arrhythmogenesis.
We identified a novel mechanism for autonomous CaMKII activation by O-GlcNAc modification at CaMKII S279 (Fig. 4g ). Acute extracellular glucose elevation, to levels that mimic those in diabetic patients, suffices to activate CaMKII through this pathway in intact cardiac myocytes and leads to arrhythmic events in intact hearts and animals. In diabetic hearts and brains CaMKII O-GlcNAcylation is elevated and this may contribute to pathological alterations in cardiac myocytes and neurons. Indeed, this pathway may synergize with autonomous CaMKII activation by phosphorylation 8 and oxidation 26 , which are important in signalling in many cell types. CaMKIV, related to CaMKII, is O-GlcNAcylated at S189, which inhibits its activation by CaM kinase kinase 15 . O-GlcNAc-mediated activation in CaMKII is not analogous to the inhibition seen for CaMKIV.
The S279 site is highly conserved in all mammalian CaMKII isoforms (Extended Data Fig. 1e ), and the robust functional effects in cardiomyocytes suggest that hyperglycaemia can readily activate CaMKII in both heart and brain, and alter phosphorylation of multiple CaMKII targets (including CaMKII itself) to exert both acute (for example, altered Ca 21 handling/arrhythmias) and chronic (for example, transcriptional regulation) effects in many tissues. CaMKII is an important nodal point in both acute and chronic modulation of ion channels in both heart and brain. Overactivation of CaMKII caused by hyperglycaemia during diabetes may lead to widespread and as yet unappreciated pathological consequences that merit exploration. It is already known that overactivation of CaMKII occurs in heart failure and neuronal excitotoxicity, and that this activated CaMKII can contribute to major dysfunction at the level of acute ion channel modulation that contributes to cardiac arrhythmias 1,24 , reduced contractility, neuronal damage 27 and altered gene transcription 1 . In diabetes, these powerful CaMKII signalling pathways are likely to be activated by hyperglycaemia-induced O-GlcNAc modification of CaMKII, and this should be considered in future therapeutic strategies. This could also broaden the impact of CaMKII inhibitors in therapeutics in heart disease and beyond.
METHODS SUMMARY
Camui constructs were generated as previously described 7 . HEK293 cells were kept in culture for 24 h and transiently transfected with expression plasmids encoding Camui. Cells were cultured for an additional 24 h after transfection. Fluorescence measurements were performed using fluorescence spectrophotometry, excited at 440 nm with emission recorded at 477 nm for cyan fluorescent protein (CFP) (F CFP ) and 527 nm for yellow fluorescent protein (YFP) (F YFP ). Camui fluorescence and ratio (F CFP /F YFP ) was measured with 10 mM CaM plus 200 mM Ca 21 for maximal activity and with 1 mM EGTA to chelate Ca 21 for assessing deactivated or autonomous CaMKII activation. CaMKII activity was directly measured as incorporation of 32 P from ATP-cP 32 into an artificial substrate as previously described 9 . Ca 21 transients and sparks were recorded using confocal microscopy. Pooled data are represented as mean 6 s.e.m. Statistical comparisons were made with repeated twoway analysis of variance and paired Student's t-test where applicable. P , 0.05 was considered significant. 7 was incorporated in adenoviruses using the AdEasy adenoviral vector system (Qbiogene) to ensure high infection efficiency in terminally differentiated adult ventricular myocytes. Mutant variants of Camui (T286A, CM280/281VV and S279A) were generated using the commercially available QuickChange site-directed mutagenesis kit (Stratagene), and likewise incorporated into adenovirus. HEK293-cell transfection. HEK293 cells (mycoplasma free at the time of this study) were cultured in DMEM (Invitrogen) with 5% FBS and penicillin/streptomycin for 24 h, and then transiently transfected with expression plasmids encoding Camui using a mammalian transfection kit (Stratagene). Cells were cultured for an additional 36 h after transfection. Camui expression was checked by fluorescence microscopy before experiments. Human and rat models of diabetes. Failing hearts from type 2 diabetic and nondiabetic patients were obtained at the time of orthotopic heart transplantation as a gift from K. Margulies (University of Pennsylvania). Brain samples from human temporal cortex were obtained as a gift from L.-W. Jin and M. Melara (University of California, Davis). All human specimens, including failing heart tissues and brain samples, were obtained in accordance with Institutional Review Board approval at the respective institutions where samples were collected. All tissue was obtained with informed consent before transplantation surgery. Inclusion in tissue-based studies was not restricted on the basis of age, sex, race or ethnic status. Human cardiac tissue samples were divided into three groups: a non-failing and nondiabetic group (Fig. 2b control: 3 males, 3 females; ages 42-60), a heart failure group not under treatment for diabetes and with blood glucose , 200 mg dl 21 (Fig. 2b) heart failure: 3 males, 3 females; ages 41-63), and a heart failure group with diagnosed diabetes and blood glucose . 200 mg dl 21 (Fig. 2b heart failure/ diabetes: 4 males, 2 females; ages 38-66). Human brain tissue samples were divided into two groups: a non-diabetic group (Fig. 2b control: 3 females; ages 79-89), and a diabetic group with blood glucose . 200 mg dl 21 (Fig. 2b diabetes: 3 females; ages 65-82). Male Sprague-Dawley (SD) rats transgenic for human amylin in the pancreatic b-cells (HIP rats) were used at age 10-12 months as previously described 28 . Animal studies were not randomized or blinded for this study. Sample sizes were determined by power analysis or based on previous studies with the selected models 28 . Blood glucose levels in rats were measured 1 day before experiments were conducted using a OneTouch Ultra glucose meter (LifeScan; model no. AW 060-213-01A). All diabetic HIP rats had a blood glucose concentration of over 600 mg dl 21 at the time of death. In vitro fluorescence and CaMKII activity assays. Fluorescence measurements were performed using an MS SpectraMax plate reader spectrophotometer (Molecular Devices). Excitation and emission slits were set at 4 nm. An excitation wavelength of 440 nm was used, and dual photon counting emission detectors were set at 477 nm (F CFP ) and 527 nm (F YFP ), respectively. HEK cells or rat ventricular myocytes expressing Camui were treated with 10 mM CaM and 200 mM Ca 21 , then lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , and protease inhibitors to measure 'direct' activation (for example, see Fig. 1b ). For autonomous Camui fluorescence measurements, Ca 21 /CaM treatment was performed in the presence of 100-500 mg dl 21 glucose (Fig. 1b, d , e, g), 100 mM ATP (Fig. 1c ) or 1 mM H 2 O 2 (Fig. 1c ). Cell lysis was then performed in a buffer containing 1 mM EGTA to chelate Ca 21 and isolate the kinase activity attributed to autonomous (rather than direct) activation. In Fig. 1d , cells were pretreated with 1 mM EGTA or 10 mM KN-92/KN-93. In Fig. 1e , myocytes were not directly treated with Ca 21 / CaM, but instead were subjected to pacing (0.5 Hz) or treated with Iso (100 nM) in the presence of 100 or 240 mg dl 21 glucose. In Fig. 1g , cells were treated with Ca 21 / CaM and increasing glucose concentration in the presence of either 50 mM DON or 100 nM Thm-G. In Fig. 1f , CaMKII kinase activity was determined at increasing glucose concentrations and in the presence (and absence) of Iso using a kinase assay that measures incorporation of 32 P-ATP into an artificial substrate, syntide-2, as previously described 9 (Fig. 1f) . ETD-MS analysis. The peptide was analysed using an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific) with ETD. The synthetic peptide was O-GlcNAcylated by in vitro labelling with OGT overnight at 4 uC. After the O-GlcNAcylation reaction, the pH was adjusted to approximately 3 using 10% formic acid, and the sample was desalted with a C18 spin column (The Nest Group). The desalted sample was lyophilized to dryness using a Speed Vac concentrator and reconstituted in 50% methanol, 0.2% acetic acid to a final concentration of 10 pmol ml 21 . The sample was directly infused into the LTQ-Orbitrap XL mass spectrometer at a flow rate of 1 ml min 21 using a spray voltage of 1.9 kV. The full MS scans were acquired in the FT analyser with the following parameters: resolution 100,000; mass scan range mass-to-charge ratio (m/z) 300-800; and microscans 1. The ETD-MS2 scans were acquired in the ion-trap analyser with the following parameters: reagent AGC target 4 3 10 5 ; mass scan range m/z 250-2,000; microscans 1; isolation width m/z 1; and ETD activation time 80 ms.
METHODS

Construction of adenoviral vectors encoding biosensors. The Camui construct
Myocyte isolation and adenoviral infection. All protocols involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the University of California, Davis Institutional Animal Care and Use Committee. Adult rat ventricular myocytes were isolated as previously described 22 . Myocytes were seeded on laminin-coated coverslips in serum-free PC-1 medium (Lonza) supplemented with penicillin/streptomycin. Myocytes were infected for 2 h at a multiplicity of infection of 10-100 with adenovirus encoding Camui, followed by replacement with fresh medium. Infected cells were kept in culture for 36 h with one final replacement of fresh medium 1 h before experiments. Confocal microscopy imaging. Coverslips were mounted on the stage of an inverted microscope (Zeiss, LSM5 Pascal) equipped with a 40 3 1.4 NA water immersion objective lens. Argon laser excitation wavelengths were 458 nm for CFP and 514 nm for YFP. CFP emission fluorescence was measured by confocal microscopy at 485 6 15 nm, and YFP emission fluorescence was measured at $535 nm. Camui imaging experiments were performed as previously described 7 . ImageJ software was used for image analysis. Spark measurements. Intact ventricular myocytes were loaded with Fluo-3 AM (5 mM; Molecular Probes) and transients were recorded as previously described 29 . Ca 21 transients were obtained by field stimulation at 1 Hz. Sarcoplasmic reticulum Ca 21 load was evaluated by the Ca 21 transient upon rapid caffeine application (10 mM). Experiments were performed with confocal microscopy (BioRad, Radiance 2100, 340 objective) using line scan mode with argon 4 laser (excitation at 488 nm, emission at .505 nm). Image analysis used ImageJ software and homemade routines in interactive data language (IDL). Langendorff-perfused rat hearts. All procedures involving animals were approved by the Animal Care and Use Committee of the University of California, Davis and adhered to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. Adult male Sprague-Dawley rats (250-300 g) were anaesthetized with pentobarbital sodium (150 mg kg 21 , intraperitoneal (IP)) containing 500 IU kg 21 of heparin. After a midsternal incision, hearts were rapidly excised and Langendorff perfused at 37 uC with oxygenated (95% O 2 , 5% CO 2 ) modified Tyrode's solution of the following composition (in mmol l 21 ): NaCl 128.2, CaCl 2 1.3, KCl 4.7, MgCl 2 1.05, NaH 2 PO 4 1.19, NaHCO 3 20 and glucose 11.1 (pH 7.4). Flow rate (6-15 ml min 21 ) was adjusted to maintain a perfusion pressure of 60-70 mm Hg. One leaflet of the mitral valve was carefully damaged with sharp forceps inserted through the pulmonary vein to prevent solution congestion in the left ventricular cavity after suppression of ventricular contraction. This also prevented acidification of the perfusate and the development of ischaemia in the left ventricle. Two Ag/AgCl disc electrodes were positioned in the bath to record an ECG analogous to a lead I configuration. ECG was continuously recorded throughout the duration of the experiment. A bipolar pacing electrode was positioned on the base of the left ventricular epicardium for pacing, which was performed at a basic cycle length (BCL) of 200 ms using a 2 ms pulse width at twice the diastolic threshold. Dual optical mapping of V m and Ca 21 . Hearts were loaded with the fluorescent intracellular Ca 21 indicator Rhod-2 AM (Molecular Probes; 250 ml of 1 mg ml 21 in dimethylsulphoxide (DMSO) containing 10% pluronic acid) and were subsequently stained with the voltage-sensitive dye RH237 (Molecular Probes; 25 ml of 1 mg ml 21 in DMSO). Blebbistatin (Tocris Bioscience; 10-20 mM) was added to the perfusate to eliminate motion artefact during optical recordings. The anterior epicardial surface was excited using LED light sources centred at 530 nm and band-pass filtered from 511-551 nm (LEX-2; SciMedia) and focused directly on the surface of the preparation. The emitted fluorescence was collected through a 50 mm objective (Nikon) and split with a dichroic mirror at 630 nm (Omega). The longer wavelength moiety, containing the V m signal, was long-pass filtered at 700 nm, and the shorter wavelength moiety, containing the Ca 21 signal, was band-pass filtered between 574-606 nm. The emitted fluorescence signals were recorded using two CMOS cameras (MiCam Ultima-L; SciMedia) with a sampling rate of 1 kHz and 100 3 100 pixels with a 20 3 20 mm field of view. The atrioventricular node was ablated using a fine-tip thermal cautery (Acuderm) to produce a slow intrinsic rhythm which allowed for ectopic activity and PVCs to escape. After loading the dyes, baseline electrophysiological parameters were recorded during normal rhythm as well as left ventricular epicardial pacing at a BCL of 200 ms. Hearts were then subjected to hyperglycaemia (400 mg dl 21 ) with (n 5 3) or without (n 5 5) pre-treatment (10 min) with the O-GlcNAc inhibitor DON (50 mM). Optical recordings were taken every 5 min after treatment and ECG was continuously recorded. In vivo ECG recordings. In vivo experiments were performed in anaesthetized diabetic rats (blood glucose .500 mg dl 21 ). Rats received an injection of caffeine (IP; 120 mg kg 21 ) and dobutamine (intravenous; 50 mg kg 21 ) during in vivo experiments. The same individuals were pre-treated (30 min before caffeine/dobutamine challenge) with an IP injection of DON (5 mg kg 21 ). Experiments were LETTER RESEARCH done 1 week apart, and some individuals received the reverse of the described procedure (1DON in first trial, 2DON in second trial) to control for compensation effects between trials. For quantification of arrhythmia scores, the severity of arrhythmias was quantified using a previously published scoring system 30 . Each individual heart was evaluated by means of a 5-point arrhythmia score, where single PVCs were given a score of 1, bigeminy/salvos a score of 2, ventricular tachycardia a score of 3, ventricular fibrillation a score of 4, spontaneous ventricular fibrillation a score of 5, and an assigned number corresponded to the most severe type of arrhythmia observed in that heart. Scores were used for group analysis of severity of arrhythmias. Optical mapping data analysis and statistics. Optical mapping data analysis was performed using two different commercially available analysis programs (BV_Analyze, Brainvision; and Optiq, Cairn). V m and Ca 21 data sets were spatially aligned and processed with a Gaussian spatial filter (radius 3 pixels). For both action potentials and Ca 21 transients (CaTs), activation time was determined as the time at 50% between diastolic and peak amplitude. Diastolic Ca 21 elevation was measured as the percentage of diastolic Ca 21 increase relative to the following CaT amplitude at baseline and 30 min post-treatment. The average diastolic Ca 21 elevation was calculated for each heart by averaging all Ca 21 signals from the entire anterior surface of the heart within the optical mapping field of view. PVC incidence was determined from the continuous ECG recording as the number of PVCs that occurred during a 15 min period of baseline activity (before initiation of treatment) and during the first 15 min of treatment.
All values are presented as mean 6 s.e.m.; n values are generally biological replicates (hearts, brains, animals, myocytes, cell preparations) as indicated in legends. In addition, three technical replicates (triplicates) from three biological replicates were used for some cellular Camui experiments in Fig. 1 . Comparisons between two groups of data were made using a Student's t-test, paired where appropriate or with repeated two-way analysis of variance. P , 0.05 was considered statistically significant. 
